- DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
-
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
- -
-
-
- ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
-
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
- -
-
-
- Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase
-
The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.
- Adams, Nicholas D.,Adams, Jerry L.,Burgess, Joelle L.,Chaudhari, Amita M.,Copeland, Robert A.,Donatelli, Carla A.,Drewry, David H.,Fisher, Kelly E.,Hamajima, Toshihiro,Hardwicke, Mary Ann,Huffman, William F.,Koretke-Brown, Kristin K.,Lai, Zhihong V.,McDonald, Octerloney B.,Nakamura, Hiroko,Newlander, Ken A.,Oleykowski, Catherine A.,Parrish, Cynthia A.,Patrick, Denis R.,Plant, Ramona,Sarpong, Martha A.,Sasaki, Kosuke,Schmidt, Stanley J.,Silva, Domingos J.,Sutton, David,Tang, Jun,Thompson, Christine S.,Tummino, Peter J.,Wang, Jamin C.,Xiang, Hong,Yang, Jingsong,Dhanak, Dashyant
-
experimental part
p. 3973 - 4001
(2010/08/07)
-
- Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors
-
The present invention provides pyrrolo pyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
- -
-
Page/Page column 18-19
(2009/01/24)
-
- NOVEL COMPOUNDS
-
The present invention relates to compounds of formula (I): and processes for preparing them, compositions containing them and their use in treating diseases relating to inappropriate c-Met activity.
- -
-
Page/Page column 54
(2008/12/05)
-
- Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors
-
The synthesis of a 7-azaindole series of novel, potent B-Raf kinase inhibitors using knowledge-based design was carried out. Compound 6h exhibits not only excellent potency in both the enzyme assay (IC50 = 2.5 nM) and the cellular assay (ICsub
- Tang, Jun,Hamajima, Toshihiro,Nakano, Masato,Sato, Hideyuki,Dickerson, Scott H.,Lackey, Karen E.
-
scheme or table
p. 4610 - 4614
(2009/04/08)
-
- INHIBITORS OF Akt ACTIVITY
-
Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
- -
-
Page/Page column 96
(2010/11/27)
-